Full-Time

Director – And Execution Lead

Launch Preparedness, Policy & Advocacy Strategy

Posted on 7/6/2026

Deadline 7/21/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$230.9k - $384.8k/yr

No H1B Sponsorship

Remote in USA + 1 more

More locations: New York, NY, USA

Remote

Remote within the United States; occasional travel up to 40%.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis

Get referred to Pfizer

Find people who can refer or advise you

Requirements
  • MD/DO degree required and 5+ years of relevant experience
  • Demonstrated success operating with enterprise or national accountability and influencing outcomes across highly matrixed organizations
  • Deep expertise in U.S. vaccine policy, ACIP processes, medical society engagement, and payer and coverage landscapes
  • Proven ability to lead complex, high‑visibility, and policy‑sensitive initiatives through influence and governance, without direct people management responsibility
  • Experience serving as a strategic advisor to senior and executive leadership, including VP‑level stakeholders
  • Strong strategic mindset with the ability to operate effectively in ambiguity and translate complexity into clear enterprise direction and executional standards
  • Excellent written and verbal communication skills, with demonstrated success engaging senior internal and external stakeholders
  • Ability to travel up to 40 percent, including overnight travel, and comply with Pfizer corporate travel policies and procedures
Responsibilities
  • Set and govern national launch preparedness strategy and operating standards for priority U.S. vaccine and drug launches, with an initial focus on the Lyme Vaccine (LB6V) and flexibility to support additional assets as portfolio priorities evolve
  • Define, maintain, and govern enterprise‑wide launch readiness standards, success metrics, and policy‑related readiness expectations for Vaccines Field Medical, ensuring consistent application across assets and field teams
  • Serve as the escalation authority for policy‑driven risks and access barriers that may impact launch timing, uptake, or sustainability, providing strategic recommendations and decision support to U.S. Medical Affairs and Commercial leadership
  • Partner with HQ Brand Medical leads and cross‑functional stakeholders, including Commercial, Operations, Medical Analytics, and Vaccines Field Medical leadership, to anticipate and shape national field deployment models, engagement priorities, and enablement strategies, without duplicating asset‑level strategy ownership
  • Provide enterprise oversight and strategic direction for Pre‑Approval Information Exchange (PIE) readiness and execution, ensuring consistent governance, insight synthesis, and readiness expectations across launches
  • Leverage enterprise‑level medical insights, analytics, and engagement data to continuously refine launch preparedness frameworks and optimize field medical effectiveness at scale
  • Provide strategic oversight and direction for the development and deployment of launch‑related training, playbooks, and field readiness materials, ensuring alignment with enterprise standards and policy‑informed engagement expectations
  • Ensure scalable, repeatable, and policy‑integrated launch preparedness approaches are applied across pipeline and in‑line assets, rather than asset‑specific or ad hoc execution models
  • Lead and shape enterprise field medical engagement across national organizations, including ACOG, AAP, IDSA, ACP, AAFP, and other relevant professional societies, governing engagement frameworks rather than executing all interactions directly
  • Act as a strategic bridge between HQ and Field Medical teams, ensuring bidirectional communication, enterprise alignment, and executional clarity related to launch, policy, and advocacy strategy
  • Influence Scientific Engagement Leads, Field Medical society leads, and Field Medical stakeholders through subject‑matter expertise, strategic guidance, and escalation authority, rather than formal people leadership
  • Establish and reinforce enterprise standards and guidance for policy‑related field medical messaging and engagement approaches, ensuring consistency and confidence across teams and assets
  • Incorporate field feedback, external insights, and evolving policy dynamics to continuously refine enterprise launch preparedness and advocacy execution frameworks
Desired Qualifications
  • Prior experience supporting U.S. vaccine or specialty product launches, including pre‑approval readiness and cross‑functional field enablement
  • Experience working closely with or engaging U.S. medical societies, guideline‑setting bodies, or policy‑influencing organizations

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Obesity asset MET097i targets 2028 launch to offset $17B–$18B patent cliff losses.
  • Oncology revenues grew 7% to $3.8B in Q1 2026, driven by Padcev and Lorbrena.
  • FDA approval for Padcev-Keytruda expands bladder cancer treatment to earlier disease stages.

What critics are saying

  • Eliquis, Ibrance, Xtandi, and Prevnar 13 lose exclusivity by 2028, dropping $17B revenue.
  • Sigvotatug vedotin failed Phase 3 for lung cancer, weakening Seagen's oncology pipeline de-risking.
  • Cash flow fell $700M short of covering dividends in 2025, pressuring the 7% yield.

What makes Pfizer unique

  • Pfizer leads with four marketed antibody-drug conjugates from its $43B Seagen acquisition.
  • The company offers a monthly GLP-1 obesity drug, berobenatide, from Metsera.
  • Patent-protected Padcev-Keytruda regimen is the first platinum-free option for bladder cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE